Find Age-Related Macular Degeneration (ARMD) Clinical Trials Near You
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Status: Recruiting
Location: See all (39) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit.
• Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 78 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).
• For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit.
Locations
United States
California
California Retina Consultants
RECRUITING
Bakersfield
The Retina Partners
RECRUITING
Encino
Global Research Management, Inc.
RECRUITING
Glendale
Northern California Retina Vitreous Associates Medical Group INC.
RECRUITING
Mountain View
Retina Consultants of San Diego
RECRUITING
Poway
California Eye Specialists Medical Group, Inc.
RECRUITING
Redlands
Retinal Consultants Medical Group
RECRUITING
Sacramento
Retinal Consultants Medical Group - Parkcenter Drive